SUBSCRIBE
SUBSCRIBE

Novartis

NEWS
Job Trends
Novartis AG Eliminates 89 Jobs in New York
March 20, 2015
 · 
3 min read
EXCLUSIVE: DNAnexus, Stanford Genomic Catalog Will Accelerate Science in the Field, Says CEO
Policy
Amgen Devastated as Novartis AG Wins Approval to Sell First-of-a-Kind Copycat Drug
March 20, 2015
 · 
4 min read
Policy
Ex-Workers Accuse Novartis AG’s Alcon of Being Sexist, Maintaining a Boy’s Club Atmosphere
March 18, 2015
 · 
3 min read
Job Trends
Novartis AG Employees Brace for More Cuts and Consolidation
March 11, 2015
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
FDA
Novartis AG’s Sandoz Bags Approval for First Biosimilar to be Sold in the U.S.
March 6, 2015
 · 
3 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Deals
Novartis AG Unloads RNAi Portfolio to Arrowhead Research Corporation for $35 Million
March 5, 2015
 · 
3 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Deals
Novartis AG Will Move Past Scandal While Hunting for More M&A in the $2-5 Billion Range, Says CEO
March 4, 2015
 · 
4 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Policy
Novartis AG Japan Ordered to Halt Business for 15 Days
February 27, 2015
 · 
2 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Deals
Bay Area’s Pharmacyclics Mulls Possible $18 Billion Sale; Johnson & Johnson,Novartis AG Interested
February 26, 2015
 · 
2 min read
Load More
AWARDS
  • 2022 Best Places to Work
  • 2024 Best Places to Work
JOBS
IN THE PRESS
National Institute for Clinical Excellence (NICE) Backs Novartis AG’s Tasigna for CML, Rejects Bristol-Myers Squibb Company’s Sprycel
January 13, 2012
 · 
1 min read
Job Trends
Novartis AG Cuts 2,000 U.S. Jobs After Drug Setback
January 13, 2012
 · 
1 min read
Novartis AG Unit to Take $120 Million Charge on Recall, Initiates Precautionary Recall of 4 OTC Brands
January 9, 2012
 · 
1 min read
Drug Development
Phase III Trial Confirms Safety Profile of Novartis AG MS Pill
December 15, 2011
 · 
9 min read
Novartis AG: Patient Died After Starting Gilenya
December 13, 2011
 · 
1 min read
Drug Development
Two Novartis AG Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec®
December 13, 2011
 · 
23 min read
Drug Development
Latest Data on Novartis AG Afinitor Confirms Efficacy
December 8, 2011
 · 
1 min read
Policy
FDA Cites Violations at Three Novartis AG Plants
December 7, 2011
 · 
1 min read
Job Trends
Novartis AG to Shut Down Brain Research Facility; Redirects Psychiatric Efforts to Genetics
December 7, 2011
 · 
1 min read
Business
Novartis AGi’s Canadian Sales Subsidiary Celebrates Official Introduction to Canada
December 5, 2011
 · 
1 min read
Load More